ClinicalTrials.gg
CompletedNCT02347657Updated Jun 12, 2018Results posted

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

A Phase 3 interventional study of VX-661 Plus Ivacaftor Combination and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 75 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-06-12.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
2nd of 43
510 · median 100
Started
2015
with 4 others
Phase 3
25 of 43
none open now
Registered
4th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 2nd largest by enrollment, is one of 5 that started in 2015, is one of 25 in phase 3, and was the 4th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double blind, placebo controlled, parallel group, multicenter study in people with cystic fibrosis (CF) who are homozygous for the F508del CF transmembrane conductance regulator (CFTR) gene mutation.

Read the detailed description

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in people with CF who are homozygous for the F508del-CFTR mutation. This study is designed to evaluate the efficacy and safety of VX-661 in combination with Ivacaftor (IVA, VX-770). The active treatment regimen comprised of a morning dose of a fixed-dose combination (FDC) tablet of 100 milligram (mg) VX-661/150 mg IVA once daily (qd) and an evening dose of IVA 150 mg to be taken approximately 12 hours after the morning dose. The placebo regimen was visually matched tablets to be taken with the same schedule as the active treatment.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Homozygous for the F508del CFTR Mutation
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Homozygous for the F508del CFTR mutation, genotype to be confirmed at the Screening Visit
  • Confirmed diagnosis of CF defined as a sweat chloride value ≥60 mmol/L by quantitative pilocarpine iontophoresis
  • Forced expiratory volume at one second () ≥40% and ≤90% of predicted normal for age, sex, and height during screening
  • Stable CF disease as judged by the investigator
  • Willing to remain on a stable CF medication regimen through Week 24 or, if applicable, the Safety Follow up Visit

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1 (first dose of study drug)
  • Pregnant or nursing females (females of must have a negative pregnancy test at Screening and Day 1)
  • Sexually active participants of who are not willing to follow the requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
510 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.

    Drug: VX-661 Plus Ivacaftor Combination Placebo · Drug: Ivacaftor placebo

  • Experimental
    VX-661/IVA

    VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.

    Drug: VX-661 Plus Ivacaftor Combination · Drug: Ivacaftor

Interventions

  • DrugVX-661 Plus Ivacaftor Combination

    Drug pages: Tezacaftor · Ivacaftor

    FDC tablet, oral use

  • Tablet, oral use

  • DrugVX-661 Plus Ivacaftor Combination Placebo

    FDC tablet, oral use

  • DrugIvacaftor placebo

    Tablet, oral use

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Day 1, Through Week 24

Secondary outcomes

  1. Relative Change From Baseline (Day 1) in ppFEV1 Through Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Day 1, Through Week 24

  2. Number of Pulmonary Exacerbations Per Year

    Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Pulmonary exacerbation events per year (48 weeks) were reported.

    Time frame: Day 1 through Week 24

  3. Absolute Change From Baseline (Day 1) Body Mass Index (BMI) at Week 24

    BMI was defined as weight in kilograms (kg) divided by height in square meter (m\^2).

    Time frame: Day 1, Week 24

  4. Absolute Change From Baseline (Day 1) in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Day 1, Through Week 24

  5. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.

    Time frame: Day 1 up to Week 28

  6. Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24

    Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Time to event data was not collected and instead, Number of Subjects with first event were collected and are reported. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.

    Time frame: Day 1 through Week 24

  7. Absolute Change From Baseline (Day 1) in Sweat Chloride Through Week 24

    Sweat samples were collected using an approved collection device.

    Time frame: Day 1, Through Week 24

  8. Absolute Change From Baseline (Day 1) in BMI Z-score at Week 24 in Participants Less Than (<) 20 Years Old at the Time of Screening)

    BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score).

    Time frame: Day 1, Week 24

  9. Absolute Change From Baseline (Day 1) in Body Weight at Week 24

    Time frame: Day 1, Week 24

  10. Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661 and M2-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)

    This outcome was not planned to be assessed in Placebo arm.

    Time frame: Pre-morning dose on Week 16

07

Results

Posted Jun 12, 2018

Participant flow

The study was conducted across 91 sites in 12 countries.

Participant flow — Overall Study
MilestonePlaceboVX-661/IVA
Started259251
Treated258251
Completed241236
Not completed1815
Withdrew: Physician decision01
Withdrew: Adverse event84
Withdrew: Withdrawal by subject67
Withdrew: Randomized but not treated10
Withdrew: Other33

Outcome measures

PrimaryAbsolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Day 1, Through Week 24
Reported as:
Least squares mean · Percentage of predicted FEV1
Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24
Percentage of predicted FEV1PlaceboVX-661/IVA
Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24-0.6 (-1.3 to 0.0)3.4 (2.7 to 4.0)
Statistical analysis
  • Placebo vs VX-661/IVA · Mixed model for repeated measures (MMRM) · p = <0.0001 · Least squares (ls) mean difference: 4.0 · 95% CI 3.1 to 4.8
SecondaryRelative Change From Baseline (Day 1) in ppFEV1 Through Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Day 1, Through Week 24
Reported as:
Least squares mean · percent change
Relative Change From Baseline (Day 1) in ppFEV1 Through Week 24
percent changePlaceboVX-661/IVA
Relative Change From Baseline (Day 1) in ppFEV1 Through Week 24-0.5 (-1.7 to 0.6)6.3 (5.1 to 7.4)
Statistical analysis
  • Placebo vs VX-661/IVA · MMRM · p = <0.0001 · Ls mean difference: 6.8 · 95% CI 5.3 to 8.3
SecondaryNumber of Pulmonary Exacerbations Per Year

Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Pulmonary exacerbation events per year (48 weeks) were reported.

Time frame:
Day 1 through Week 24
Reported as:
Number · pulmonary exacerbation events per year
Number of Pulmonary Exacerbations Per Year
pulmonary exacerbation events per yearPlaceboVX-661/IVA
Number of Pulmonary Exacerbations Per Year0.990.64
Statistical analysis
  • Placebo vs VX-661/IVA · Negative Binomial Regression · p = 0.0054 · Event rate ratio: 0.65 · 95% CI 0.48 to 0.88
SecondaryAbsolute Change From Baseline (Day 1) Body Mass Index (BMI) at Week 24

BMI was defined as weight in kilograms (kg) divided by height in square meter (m\^2).

Time frame:
Day 1, Week 24
Reported as:
Least squares mean · kilogram per square meter (kg/m^2)
Absolute Change From Baseline (Day 1) Body Mass Index (BMI) at Week 24
kilogram per square meter (kg/m^2)PlaceboVX-661/IVA
Absolute Change From Baseline (Day 1) Body Mass Index (BMI) at Week 240.12 (0.03 to 0.22)0.18 (0.08 to 0.28)
Statistical analysis
  • Placebo vs VX-661/IVA · MMRM · p = 0.4127 · Ls mean difference: 0.06 · 95% CI -0.08 to 0.19
SecondaryAbsolute Change From Baseline (Day 1) in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Day 1, Through Week 24
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline (Day 1) in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24
units on a scalePlaceboVX-661/IVA
Absolute Change From Baseline (Day 1) in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24-0.1 (-1.6 to 1.4)5.0 (3.5 to 6.5)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.

Time frame:
Day 1 up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboVX-661/IVA
Participants with AEs245227
Participants with SAEs4731
SecondaryNumber of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24

Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Time to event data was not collected and instead, Number of Subjects with first event were collected and are reported. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.

Time frame:
Day 1 through Week 24
Reported as:
Count of participants · Participants
Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24
ParticipantsPlaceboVX-661/IVA
Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 248862
SecondaryAbsolute Change From Baseline (Day 1) in Sweat Chloride Through Week 24

Sweat samples were collected using an approved collection device.

Time frame:
Day 1, Through Week 24
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change From Baseline (Day 1) in Sweat Chloride Through Week 24
millimole per liter (mmol/L)PlaceboVX-661/IVA
Absolute Change From Baseline (Day 1) in Sweat Chloride Through Week 240.2 (-0.8 to 1.2)-9.9 (-10.9 to -8.9)
SecondaryAbsolute Change From Baseline (Day 1) in BMI Z-score at Week 24 in Participants Less Than (<) 20 Years Old at the Time of Screening)

BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score).

Time frame:
Day 1, Week 24
Reported as:
Least squares mean · z-score
Absolute Change From Baseline (Day 1) in BMI Z-score at Week 24 in Participants Less Than (<) 20 Years Old at the Time of Screening)
z-scorePlaceboVX-661/IVA
Absolute Change From Baseline (Day 1) in BMI Z-score at Week 24 in Participants Less Than (<) 20 Years Old at the Time of Screening)-0.02 (-0.10 to 0.06)-0.06 (-0.14 to 0.02)
SecondaryAbsolute Change From Baseline (Day 1) in Body Weight at Week 24
Time frame:
Day 1, Week 24
Reported as:
Least squares mean · kg
Absolute Change From Baseline (Day 1) in Body Weight at Week 24
kgPlaceboVX-661/IVA
Absolute Change From Baseline (Day 1) in Body Weight at Week 240.6 (0.3 to 0.9)0.7 (0.4 to 1.0)
SecondaryTrough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661 and M2-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)

This outcome was not planned to be assessed in Placebo arm.

Time frame:
Pre-morning dose on Week 16
Reported as:
Mean · nanogram per milliliter (ng/mL)
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661 and M2-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
nanogram per milliliter (ng/mL)VX-661/IVA
VX-6611890 ± 1150
M1 VX-6614730 ± 1730
M2 VX-6614830 ± 2750
IVA815 ± 572
M1 IVA1590 ± 961

Adverse events

Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/258 (0%)47/258 (18.2%)243/258 (94.2%)
VX-661/IVA0/251 (0%)31/251 (12.4%)227/251 (90.4%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPlaceboVX-661/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations32/25823/251
HaemoptysisRespiratory, thoracic and mediastinal disorders3/2583/251
PneumoniaInfections and infestations1/2582/251
ConstipationGastrointestinal disorders2/2580/251
Acute kidney injuryRenal and urinary disorders2/2580/251
Clostridium difficile colitisInfections and infestations0/2581/251
Lung abscessInfections and infestations0/2581/251
Respiratory tract infection viralInfections and infestations0/2581/251
Benign intracranial hypertensionNervous system disorders0/2581/251
Generalised tonic-clonic seizureNervous system disorders0/2581/251
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboVX-661/IVA
CoughRespiratory, thoracic and mediastinal disorders83/25866/251
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations75/25857/251
HeadacheNervous system disorders36/25844/251
NasopharyngitisInfections and infestations39/25842/251
Sputum increasedRespiratory, thoracic and mediastinal disorders42/25836/251
HaemoptysisRespiratory, thoracic and mediastinal disorders33/25824/251
PyrexiaGeneral disorders32/25828/251
FatigueGeneral disorders30/25816/251
Oropharyngeal painRespiratory, thoracic and mediastinal disorders29/25822/251
Abdominal painGastrointestinal disorders22/25823/251

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who carried the intended cystic fibrosis transmembrane conductance regulator (CFTR) allele mutation and had received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboVX-661/IVATotal
Mean25.7 ± 9.526.9 ± 11.226.3 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVX-661/IVATotal
Female125121246
Male131127258
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboVX-661/IVATotal
Hispanic or Latino3912
Not Hispanic or Latino250234484
Unknown or Not Reported358
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboVX-661/IVATotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American011
White254245499
More than one race000
Unknown or Not Reported022
08

Study locations

75 sites
  • Little Rock, Arkansas, United States
  • Long Beach, California, United States
  • Denver, Colorado, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Peoria, Illinois, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Manchester, New Hampshire, United States
  • Long Branch, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • Buffalo, New York, United States
  • New Hyde Park, New York, United States
  • Rochester, New York, United States
  • Syracuse, New York, United States
  • Akron, Ohio, United States
  • Columbus, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Charleston, South Carolina, United States
  • Sioux Falls, South Dakota, United States
  • Fort Worth, Texas, United States
  • Tyler, Texas, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Calgary, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Halifax, Nova Scotia, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Copenhagen O, Denmark
  • Marseille cedex 20, Bouches-du-Rhone, France
  • Roscoff, Finistere, France
  • Bordeaux, Girande, France
  • Lille Cedex, Nord, France
  • Paris cedex 14, Paris, France
  • Paris Cedex 19, Paris, France
  • Pierre Benite cedex, Rhone, France
  • Heidelberg, Baden Wuerttemberg, Germany
  • Muenchen, Bayern, Germany
  • Wuerzburg, Bayern, Germany
  • Belfast, Berlin, Germany
  • Frankfurt, Hessen, Germany
  • Giessen, Hessen, Germany
  • Berlin, Germany
  • Cork, Ireland
  • Dublin, Ireland
  • Genova, Italy
  • Palermo, Italy
  • Roma, Italy
  • Torino, Italy
  • Verona, Italy
  • Den Haag, Netherlands
  • Groningen, Netherlands
  • Nijmegen, Netherlands
  • Rotterdam, Netherlands
  • Utrecht, Netherlands
  • Barcelona, Spain
  • Madrid, Spain
  • Sevilla, Spain
  • Valencia, Spain
  • Goteborg, Sweden
  • Stockholm, Sweden
  • Uppsala, Sweden
  • Bern, Switzerland
  • Zuerich, Switzerland
  • Exeter, Devon, United Kingdom
  • Liverpool, Lancashire, United Kingdom
  • Sheffield, South Yorkshire, United Kingdom
  • Newcastle Upon Tyne, Tyne & Wear, United Kingdom
  • Birmingham, West Midlands, United Kingdom
  • Belfast, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 Nov 23;377(21):2013-2023. doi: 10.1056/NEJMoa1709846. Epub 2017 Nov 3. PubMed 29099344 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Jan 2017, 24 months.

Results were first posted in Jun 2018, 1 year 4 months after primary completion. A results delay was requested in Feb 2018.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 24 months is close to that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2015
First posted
Jan 27, 2015
StartActual
Jan 2015
Primary completionActual
Jan 20, 2017
CompletionActual
Jan 20, 2017
Results delay requested
Feb 14, 2018
Results first posted
Jun 12, 2018
Last update
Jun 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02347657
Responsible party
Sponsor
First posted
Jan 27, 2015
Start date
Jan 2015
Primary completion
Jan 20, 2017
Completion
Jan 20, 2017
Results posted
Jun 12, 2018
Last update
Jun 12, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion